{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T21:57:47Z","timestamp":1787954267825,"version":"build-2784847793"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014337","name":"Menarini Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Delafloxacin is a novel fluoroquinolone with broad antibacterial activity against pathogens causing acute bacterial skin and skin structure infections (ABSSSI). This network meta-analysis (NMA) was conducted to evaluate the relative efficacy of delafloxacin versus other comparators used for managing patients with ABSSSI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic literature review was conducted to identify randomised controlled trials (RCTs) evaluating adults (\u2265\u200918\u00a0years) with ABSSSI, complicated SSSI (cSSSI), complicated skin and soft tissue infections (cSSTI) or severe cellulitis with pathogen of gram-positive, gram-negative, or mixed aetiology. OVID MEDLINE<jats:sup>\u00ae<\/jats:sup>, Embase, Epub Ahead of Print, Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews were searched from inception through 12 April 2019. A feasibility assessment was conducted, followed by an NMA, which was run in a Bayesian framework. The interventions included in the NMA encompassed monotherapy or combination therapies of amoxicillin\/clavulanate, ampicillin\/sulbactam, ceftaroline, ceftobiprole, dalbavancin, daptomycin, delafloxacin, fusidic acid, iclaprim, linezolid, omadacycline, oxacillin\u2009+\u2009dicloxacillin, standard therapy, tedizolid, telavancin, tigecycline, vancomycin, vancomycin\u2009+\u2009aztreonam and vancomycin\u2009+\u2009linezolid.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A feasibility assessment was performed and evidence networks were established for composite clinical response (n\u2009=\u200934 studies), early clinical response (n\u2009=\u200916 studies) and microbiological response (n\u2009=\u200914 studies) in the overall study population, composite clinical response (n\u2009=\u20094 studies) in obese subpopulation and for composite clinical response (n\u2009=\u200918 studies) and microbiological response (n\u2009=\u200914 studies) in patients with methicillin-resistant<jats:italic>Staphylococcus aureus<\/jats:italic>(MRSA) infection. Delafloxacin performed significantly better than fusidic acid, iclaprim, vancomycin, and ceftobiprole for composite clinical response. Delafloxacin was comparable to dalbavancin, daptomycin, fusidic acid, iclaprim, linezolid, omadacycline, tedizolid, vancomycin, vancomycin\u2009+\u2009aztreonam and vancomycin\u2009+\u2009linezolid in the analysis of early clinical response, whereas for microbiological response, delafloxacin was comparable to all interventions. In the obese subpopulation, the results favoured delafloxacin in comparison to vancomycin, whilst the results were comparable with other interventions among the MRSA subpopulation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Delafloxacin is a promising new antibiotic for ABSSSI demonstrating greater improvement (composite clinical response) compared to ceftobiprole, fusidic acid, iclaprim, telavancin and vancomycin and comparable effectiveness versus standard of care for all outcomes considered in the study.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12879-021-06736-x","type":"journal-article","created":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T08:07:22Z","timestamp":1633421242000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparative efficacy of delafloxacin for complicated and acute bacterial skin and skin structure infections: results from a network meta-analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Ioanna","family":"Vlachaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Vacchelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Zinzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9179-682X","authenticated-orcid":false,"given":"Edel","family":"Falla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Mantopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilip","family":"Nathwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,5]]},"reference":[{"issue":"suppl_3","key":"6736_CR1","doi-asserted-by":"publisher","first-page":"iii35","DOI":"10.1093\/jac\/dkq302","volume":"65","author":"MS Dryden","year":"2010","unstructured":"Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother. 2010;65(suppl_3):iii35\u201344. https:\/\/doi.org\/10.1093\/jac\/dkq302.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"6736_CR2","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s12879-015-1071-0","volume":"15","author":"LG Miller","year":"2015","unstructured":"Miller LG, Eisenberg DF, Liu H, Chang C-L, Wang Y, Luthra R, et al. Incidence of skin and soft tissue infections in ambulatory and inpatient settings, 2005\u20132010. BMC Infect Dis. 2015;15(1):362. https:\/\/doi.org\/10.1186\/s12879-015-1071-0.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"6736_CR3","doi-asserted-by":"publisher","first-page":"A245","DOI":"10.1016\/j.jval.2015.03.1424","volume":"18","author":"GC Lee","year":"2015","unstructured":"Lee GC, Boyd NK, Lawson KA, Frei CR. Incidence and cost of skin and soft tissue infections in the United States. Value Health. 2015;18(3):A245. https:\/\/doi.org\/10.1016\/j.jval.2015.03.1424.","journal-title":"Value Health"},{"issue":"4","key":"6736_CR4","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jemermed.2014.12.001","volume":"48","author":"CV Pollack Jr","year":"2015","unstructured":"Pollack CV Jr, Amin A, Ford WT Jr, Finley R, Kaye KS, Nguyen HH, et al. Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital. J Emerg Med. 2015;48(4):508\u201319. https:\/\/doi.org\/10.1016\/j.jemermed.2014.12.001.","journal-title":"J Emerg Med"},{"key":"6736_CR5","unstructured":"USFDA. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER)Guidance for Industry. Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment 2013, https:\/\/www.fda.gov\/files\/drugs\/published\/Acute-Bacterial-Skin-and-Skin-Structure-Infections---Developing-Drugs-for-Treatment.pdf. Accessed 19 Aug 2020."},{"issue":"2","key":"6736_CR6","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1093\/cid\/ciu444","volume":"59","author":"DL Stevens","year":"2014","unstructured":"Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-52. https:\/\/doi.org\/10.1093\/cid\/ciu444.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"6736_CR7","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1128\/CMR.00134-14","volume":"28","author":"SYC Tong","year":"2015","unstructured":"Tong SYC, Davis JS, Eichenberger E, Holland TL, Fowler VG. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28(3):603. https:\/\/doi.org\/10.1128\/CMR.00134-14.","journal-title":"Clin Microbiol Rev"},{"issue":"10","key":"6736_CR8","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/jac\/dkv179","volume":"70","author":"DM Livermore","year":"2015","unstructured":"Livermore DM, Mushtaq S, Warner M, James D, Kearns A, Woodford N. Pathogens of skin and skin-structure infections in the UK and their susceptibility to antibiotics, including ceftaroline. J Antimicrob Chemother. 2015;70(10):2844\u201353. https:\/\/doi.org\/10.1093\/jac\/dkv179.","journal-title":"J Antimicrob Chemother"},{"key":"6736_CR9","unstructured":"ECDC. European Centre for Disease Prevention and Control (ECDC); Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2018, https:\/\/www.ecdc.europa.eu\/en\/publications-data\/surveillance-antimicrobial-resistance-europe-2018. Accessed 9 Aug 2020."},{"key":"6736_CR10","unstructured":"CDC. Centre for Disease Control and Prevention; Antibiotic Resistance Threats Report, https:\/\/www.cdc.gov\/drugresistance\/biggest-threats.html (2019)."},{"issue":"11","key":"6736_CR11","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1093\/cid\/cix640","volume":"65","author":"EY Klein","year":"2017","unstructured":"Klein EY, Mojica N, Jiang W, Cosgrove SE, Septimus E, Morgan DJ, et al. Trends in methicillin-resistant Staphylococcus aureus hospitalizations in the United States, 2010\u20132014. Clin Infect Dis. 2017;65(11):1921\u20133. https:\/\/doi.org\/10.1093\/cid\/cix640.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"6736_CR12","doi-asserted-by":"publisher","first-page":"214","DOI":"10.15585\/mmwr.mm6809e1","volume":"68","author":"AP Kourtis","year":"2019","unstructured":"Kourtis AP, Hatfield K, Baggs J, Mu Y, See I, Epson E, et al. Vital signs: epidemiology and recent trends in methicillin-resistant and in methicillin-susceptible Staphylococcus aureus bloodstream infections - United States. MMWR Morb Mortal Wkly Rep. 2019;68(9):214\u20139. https:\/\/doi.org\/10.15585\/mmwr.mm6809e1.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"Suppl 3","key":"6736_CR13","doi-asserted-by":"publisher","first-page":"S206","DOI":"10.1093\/cid\/ciz004","volume":"68","author":"Y Golan","year":"2019","unstructured":"Golan Y. Current treatment options for acute skin and skin-structure infections. Clin Infect Dis. 2019;68(Suppl 3):S206\u201312. https:\/\/doi.org\/10.1093\/cid\/ciz004.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"6736_CR14","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s40265-017-0764-7","volume":"77","author":"MN Jeffres","year":"2017","unstructured":"Jeffres MN. The whole price of vancomycin: toxicities, troughs, and time. Drugs. 2017;77(11):1143\u201354. https:\/\/doi.org\/10.1007\/s40265-017-0764-7.","journal-title":"Drugs"},{"issue":"2","key":"6736_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1128\/AAC.01088-08","volume":"53","author":"A Forouzesh","year":"2009","unstructured":"Forouzesh A, Moise PA, Sakoulas G. Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Antimicrob Agents Chemother. 2009;53(2):483\u20136. https:\/\/doi.org\/10.1128\/AAC.01088-08.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"6736_CR16","first-page":"30","volume":"46","author":"R Kupstaite","year":"2010","unstructured":"Kupstaite R, Baranauskaite A, Pileckyte M, Sveikata A, Kadusevicius E, Muckiene G. Severe vancomycin-induced anaphylactic reaction. Medicina (Kaunas). 2010;46(1):30\u20133.","journal-title":"Medicina (Kaunas)"},{"issue":"2","key":"6736_CR17","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.jaip.2020.09.027","volume":"9","author":"S Alvarez-Arango","year":"2021","unstructured":"Alvarez-Arango S, Yerneni S, Tang O, Zhou L, Mancini CM, Blackley SV, et al. Vancomycin hypersensitivity reactions documented in electronic health records. J Allergy Clin Immunol Pract. 2021;9(2):906\u201312. https:\/\/doi.org\/10.1016\/j.jaip.2020.09.027.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"6736_CR18","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s40265-013-0075-6","volume":"73","author":"JE Frampton","year":"2013","unstructured":"Frampton JE. Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia. Drugs. 2013;73(10):1067\u201394. https:\/\/doi.org\/10.1007\/s40265-013-0075-6.","journal-title":"Drugs"},{"issue":"Suppl 2","key":"6736_CR19","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/s1198-743x(16)30095-7","volume":"22","author":"A Russo","year":"2016","unstructured":"Russo A, Concia E, Cristini F, De Rosa FG, Esposito S, Menichetti F, et al. Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections. Clin Microbiol Infect. 2016;22(Suppl 2):S27-36. https:\/\/doi.org\/10.1016\/s1198-743x(16)30095-7.","journal-title":"Clin Microbiol Infect"},{"key":"6736_CR20","unstructured":"Allergan. USA, Inc, DALVANCE (dalbavancin) Prescribing information 2018, https:\/\/media.allergan.com\/actavis\/actavis\/media\/allergan-pdf-documents\/product-prescribing\/Dalvance_Final_PI_10_2018.pdf. Accessed 05 Oct 2020."},{"key":"6736_CR21","unstructured":"EMA. Orbactiv; EPAR; Summary of Product Characteristics; European Medicines Agency, https:\/\/www.ema.europa.eu\/en\/documents\/overview\/orbactiv-epar-summary-public_en.pdf (2015)."},{"key":"6736_CR22","unstructured":"MSD. Merck Sharp & Dohme Corp, SIVEXTRO (tedizolid phosphate) https:\/\/www.merck.com\/product\/usa\/pi_circulars\/s\/sivextro\/sivextro_pi.pdf. Accessed 05 Oct 2020."},{"key":"6736_CR23","unstructured":"WHO. World Health Organization, Antimicrobial resistance: global report on surveillance 2014, https:\/\/www.who.int\/antimicrobial-resistance\/publications\/surveillancereport\/en\/. Accessed 05 Oct 2020."},{"issue":"3","key":"6736_CR24","doi-asserted-by":"publisher","first-page":"A186","DOI":"10.1016\/j.jval.2015.03.1073","volume":"18","author":"R Ayyagari","year":"2015","unstructured":"Ayyagari R, Revol C, Tang W, Faust E, Tuttle EG. Association of Obesity with 30-day readmission rates among patients Hospitalized with Acute Bacterial Skin and Skin-Structure Infections (ABSSSI). Value in Health. 2015;18(3):A186. https:\/\/doi.org\/10.1016\/j.jval.2015.03.1073.","journal-title":"Value in Health"},{"issue":"5","key":"6736_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/2049936117723228","volume":"4","author":"A Pulido-Cejudo","year":"2017","unstructured":"Pulido-Cejudo A, Guzm\u00e1n-Gutierrez M, Jalife-Monta\u00f1o A, Ortiz-Covarrubias A, Mart\u00ednez-Ordaz JL, Noyola-Villalobos HF, et al. Management of acute bacterial skin and skin structure infections with a focus on patients at high risk of treatment failure. Therap Adv Infect Dis. 2017;4(5):143\u201361. https:\/\/doi.org\/10.1177\/2049936117723228.","journal-title":"Therap Adv Infect Dis"},{"key":"6736_CR26","unstructured":"WHO. Obesity and overweight; World Health Organization, https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight (2016)."},{"issue":"2","key":"6736_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40121-018-0198-x","volume":"7","author":"SCJ Jorgensen","year":"2018","unstructured":"Jorgensen SCJ, Mercuro NJ, Davis SL, Rybak MJ. Delafloxacin: place in therapy and review of microbiologic, clinical and pharmacologic properties. Infect Dis Ther. 2018;7(2):197\u2013217. https:\/\/doi.org\/10.1007\/s40121-018-0198-x.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"6736_CR28","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.clinthera.2015.11.014","volume":"38","author":"TP Lodise","year":"2016","unstructured":"Lodise TP, Fan W, Sulham KA. Economic impact of oritavancin for the treatment of acute bacterial skin and skin structure infections in the emergency department or observation setting: cost savings associated with avoidable hospitalizations. Clin Ther. 2016;38(1):136\u201348. https:\/\/doi.org\/10.1016\/j.clinthera.2015.11.014.","journal-title":"Clin Ther"},{"key":"6736_CR29","unstructured":"EMA. European Medicines Agency; Quofenix (delafloxacin), https:\/\/www.ema.europa.eu\/en\/documents\/overview\/quofenix-epar-medicine-overview_en.pdf. Accessed 05 Oct 2020."},{"issue":"5","key":"6736_CR30","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/cid\/ciy165","volume":"67","author":"W O'Riordan","year":"2018","unstructured":"O\u2019Riordan W, McManus A, Teras J, Poromanski I, Cruz-Saldariagga M, Quintas M, et al. A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind. Randomized Study. Clin Infect Dis. 2018;67(5):657\u201366. https:\/\/doi.org\/10.1093\/cid\/ciy165.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"6736_CR31","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.1093\/jac\/dkx329","volume":"72","author":"J Pullman","year":"2017","unstructured":"Pullman J, Gardovskis J, Farley B, Sun E, Quintas M, Lawrence L, et al. Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study. J Antimicrob Chemother. 2017;72(12):3471\u201380. https:\/\/doi.org\/10.1093\/jac\/dkx329.","journal-title":"J Antimicrob Chemother"},{"key":"6736_CR32","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2147\/idr.S202160","volume":"12","author":"SH Lan","year":"2019","unstructured":"Lan SH, Lai CC, Lu LC, Chang SP, Huang HT. Efficacy and safety of delafloxacin in the treatment of acute bacterial skin and skin structure infections: a systematic review and meta-analysis of randomized controlled trials. Infect Drug Resist. 2019;12:1415\u201323. https:\/\/doi.org\/10.2147\/idr.S202160.","journal-title":"Infect Drug Resist"},{"issue":"2","key":"6736_CR33","doi-asserted-by":"publisher","first-page":"S227","DOI":"10.1093\/ofid\/ofz360.538","volume":"6","author":"AA Alhifany","year":"2019","unstructured":"Alhifany AA, Bifari N, Alatawi Y, Ullah Malik S, Almangour T. 465. Comparative efficacy of double vs. single antibiotic regimens for the empiric treatment of MRSA-induced acute bacterial skin and skin structure infection. Open Forum Infect Dis. 2019;6(2):S227\u20138. https:\/\/doi.org\/10.1093\/ofid\/ofz360.538.","journal-title":"Open Forum Infect Dis"},{"key":"6736_CR34","unstructured":"Julian PT Higgins SG. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.02011."},{"key":"6736_CR35","doi-asserted-by":"crossref","unstructured":"Higgins JPT AD. Assessing risk of bias in included studies, In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Chichester (UK): Wiley; 2008.","DOI":"10.1002\/9780470712184"},{"key":"6736_CR36","unstructured":"Sofia Dias NJW, Alex J Sutton, and AE Ades. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials2014."},{"key":"6736_CR37","unstructured":"Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. NICE Decision Support Unit Technical Support Documents. NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials. London: National Institute for Health and Care Excellence (NICE) Copyright \u00a9 2014 National Institute for Health and Clinical Excellence, unless otherwise stated. All rights reserved.; 2014."},{"issue":"23","key":"6736_CR38","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","volume":"370","author":"GR Corey","year":"2014","unstructured":"Corey GR, Kabler H, Mehra P, Gupta S, Overcash JS, Porwal A, et al. Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections. 2014;370(23):2180\u201390. https:\/\/doi.org\/10.1056\/NEJMoa1310422.","journal-title":"Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections"},{"issue":"2","key":"6736_CR39","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/cid\/ciu778","volume":"60","author":"GR Corey","year":"2015","unstructured":"Corey GR, Good S, Jiang H, Moeck G, Wikler M, Green S, et al. Single-dose oritavancin versus 7\u201310 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis. 2015;60(2):254\u201362. https:\/\/doi.org\/10.1093\/cid\/ciu778.","journal-title":"Clin Infect Dis"},{"key":"6736_CR40","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/1471-2334-12-297","volume":"12","author":"P Matthews","year":"2012","unstructured":"Matthews P, Alpert M, Rahav G, Rill D, Zito E, Gardiner D, et al. A randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infections. BMC Infect Dis. 2012;12:297. https:\/\/doi.org\/10.1186\/1471-2334-12-297.","journal-title":"BMC Infect Dis"},{"issue":"11","key":"6736_CR41","doi-asserted-by":"publisher","first-page":"5650","DOI":"10.1128\/aac.00948-12","volume":"56","author":"GJ Noel","year":"2012","unstructured":"Noel GJ, Draper MP, Hait H, Tanaka SK, Arbeit RD. A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother. 2012;56(11):5650\u20134. https:\/\/doi.org\/10.1128\/aac.00948-12.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"6736_CR42","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1086\/595686","volume":"48","author":"MH Wilcox","year":"2009","unstructured":"Wilcox MH, Tack KJ, Bouza E, Herr DL, Ruf BR, Ijzerman MM, et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis. 2009;48(2):203\u201312. https:\/\/doi.org\/10.1086\/595686.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"6736_CR43","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1128\/aac.49.6.2260-2266.2005","volume":"49","author":"J Weigelt","year":"2005","unstructured":"Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005;49(6):2260\u20136. https:\/\/doi.org\/10.1128\/aac.49.6.2260-2266.2005.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"6736_CR44","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.amjsurg.2009.08.045","volume":"199","author":"KM Itani","year":"2010","unstructured":"Itani KM, Dryden MS, Bhattacharyya H, Kunkel MJ, Baruch AM, Weigelt JA. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am J Surg. 2010;199(6):804\u201316. https:\/\/doi.org\/10.1016\/j.amjsurg.2009.08.045.","journal-title":"Am J Surg"},{"key":"6736_CR45","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1186\/s12879-015-1261-9","volume":"15","author":"TL Kauf","year":"2015","unstructured":"Kauf TL, McKinnon P, Corey GR, Bedolla J, Riska PF, Sims M, et al. An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection. BMC Infect Dis. 2015;15:503. https:\/\/doi.org\/10.1186\/s12879-015-1261-9.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"6736_CR46","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.amjsurg.2005.01.011","volume":"189","author":"JN Sharpe","year":"2005","unstructured":"Sharpe JN, Shively EH, Polk HC Jr. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg. 2005;189(4):425\u20138. https:\/\/doi.org\/10.1016\/j.amjsurg.2005.01.011.","journal-title":"Am J Surg"},{"issue":"1","key":"6736_CR47","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ajo.2013.01.031","volume":"156","author":"N Pushker","year":"2013","unstructured":"Pushker N, Tejwani LK, Bajaj MS, Khurana S, Velpandian T, Chandra M. Role of oral corticosteroids in orbital cellulitis. Am J Ophthalmol. 2013;156(1):178-83.e1. https:\/\/doi.org\/10.1016\/j.ajo.2013.01.031.","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"6736_CR48","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1086\/429914","volume":"40","author":"ME Stryjewski","year":"2005","unstructured":"Stryjewski ME, O\u2019Riordan WD, Lau WK, Pien FD, Dunbar LM, Vallee M, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis. 2005;40(11):1601\u20137. https:\/\/doi.org\/10.1086\/429914.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"6736_CR49","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1128\/aac.50.3.862-867.2006","volume":"50","author":"ME Stryjewski","year":"2006","unstructured":"Stryjewski ME, Chu VH, O\u2019Riordan WD, Warren BL, Dunbar LM, Young DM, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother. 2006;50(3):862\u20137. https:\/\/doi.org\/10.1128\/aac.50.3.862-867.2006.","journal-title":"Antimicrob Agents Chemother"},{"key":"6736_CR50","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1128\/aac.00772-17","volume":"61","author":"S McCurdy","year":"2017","unstructured":"McCurdy S, Lawrence L, Quintas M, Woosley L, Flamm R, Tseng C, et al. In vitro activity of delafloxacin and microbiological response against fluoroquinolone-susceptible and nonsusceptible staphylococcus aureus isolates from two phase 3 studies of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2017;61:9. https:\/\/doi.org\/10.1128\/aac.00772-17.","journal-title":"Antimicrob Agents Chemother."},{"issue":"2","key":"6736_CR51","doi-asserted-by":"publisher","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","volume":"159","author":"A Cipriani","year":"2013","unstructured":"Cipriani A, Higgins JPT, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. Ann Intern Med. 2013;159(2):130\u20137. https:\/\/doi.org\/10.7326\/0003-4819-159-2-201307160-00008.","journal-title":"Ann Intern Med"},{"issue":"Suppl 4","key":"6736_CR52","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/jac\/dkq254","volume":"65","author":"GR Corey","year":"2010","unstructured":"Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(Suppl 4):41\u201351. https:\/\/doi.org\/10.1093\/jac\/dkq254.","journal-title":"J Antimicrob Chemother."},{"issue":"Suppl 4","key":"6736_CR53","doi-asserted-by":"publisher","first-page":"iv53","DOI":"10.1093\/jac\/dkq255","volume":"65","author":"MH Wilcox","year":"2010","unstructured":"Wilcox MH, Corey GR, Talbot GH, Thye D, Friedland D, Baculik T. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(Suppl 4):iv53\u201365. https:\/\/doi.org\/10.1093\/jac\/dkq255.","journal-title":"J Antimicrob Chemother."},{"issue":"10","key":"6736_CR54","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.1128\/aac.00590-07","volume":"51","author":"GH Talbot","year":"2007","unstructured":"Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother. 2007;51(10):3612\u20136. https:\/\/doi.org\/10.1128\/aac.00590-07.","journal-title":"Antimicrob Agents Chemother"},{"key":"6736_CR55","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ijid.2014.10.009","volume":"30","author":"W O'Riordan","year":"2015","unstructured":"O\u2019Riordan W, Mehra P, Manos P, Kingsley J, Lawrence L, Cammarata S. A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections. Int J Infect Dis. 2015;30:67\u201373. https:\/\/doi.org\/10.1016\/j.ijid.2014.10.009.","journal-title":"Int J Infect Dis"},{"issue":"3","key":"6736_CR56","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/jac\/dkv411","volume":"71","author":"J Kingsley","year":"2016","unstructured":"Kingsley J, Mehra P, Lawrence LE, Henry E, Duffy E, Cammarata SK, et al. A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin. J Antimicrob Chemother. 2016;71(3):821\u20139. https:\/\/doi.org\/10.1093\/jac\/dkv411.","journal-title":"J Antimicrob Chemother"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06736-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06736-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06736-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T01:09:13Z","timestamp":1699578553000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06736-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,5]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6736"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06736-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,5]]},"assertion":[{"value":"12 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval and patient consent was not required as the study is a meta-analysis based on published studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have given their consent to publishing this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MV, IV and DZ are full time employees of Menarini group. YJ, EF and TM received consulting fees from Menarini. DN supported the study as the clinical expert and received personal fee from Menarini for his support in the present study. DN has also received honoraria from Menarini outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1036"}}